首页> 外文OA文献 >Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy
【2h】

Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug-induced liver injury case-control study in Italy

机译:尼美舒利和其他NsaIDs引起急性和严重肝损伤的风险:来自意大利药物诱导的肝损伤病例对照研究的数据

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aim: Drug-induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti-inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the risk of acute and serious liver injury associated with the use of nimesulide and other NSAIDs, with a prevalence of use greater than or equal to 5%. ududMethods: This is a multicentre case–control study carried out in nine Italian hospitals from October 2010 to January 2014. Cases were adults, with a diagnosis of acute liver injury. Controls presented acute clinical disorders not related to chronic conditions, not involving the liver. Adjusted odds ratio (ORs) with 95% confidence interval (CI) were calculated initially with a bivariate and then multivariate analysis. ududResults: We included 179 cases matched to 1770 controls. Adjusted OR for acute serious liver injury associated with all NSAIDs was 1.69, 95% CI 1.21–2.37. Thirty cases were exposed to nimesulide (adjusted OR 2.10, 95% CI 1.28–3.47); the risk increased according to the length of exposure (OR > 30 days: 12.55, 95% CI 1.73–90.88) and to higher doses (OR 10.69, 95% CI 4.02–28.44). Risk of hepatotoxicity was increased also for ibuprofen, used both at recommended dosages (OR 1.92, 95% CI 1.13–3.26) and at higher doses (OR 3.73, 95% CI 1.11–12.46) and for ketoprofen ≥ 150 mg (OR 4.65, 95% CI 1.33–10.00). ududConclusion: Among all NSAIDs, nimesulide is associated with the higher risk, ibuprofen and high doses of ketoprofen are also associated with a modestly increased risk of hepatotoxicity.
机译:目的:药物引起的肝损伤是最严重的药物不良反应之一,也是限制适应症或停药的最常见原因。由于严重的肝毒性,一些非甾体类抗炎药(NSAIDs)被撤出市场。我们估计使用尼美舒利和其他NSAID会导致急性和严重肝损伤的风险,且使用率大于或等于5%。方法:这是一项从2010年10月至2014年1月在意大利9家医院进行的多中心病例对照研究。病例为成年人,诊断为急性肝损伤。对照表现出与慢性病无关的急性临床疾病,不涉及肝脏。首先使用二元分析,然后进行多变量分析,计算出具有95%置信区间(CI)的调整后优势比(OR)。 ud ud结果:我们纳入了与1770个对照匹配的179个案例。与所有NSAIDs相关的急性严重肝损伤的校正OR为1.69,95%CI 1.21-2.37。 30例暴露于尼美舒利(调整OR 2.10,95%CI 1.28–3.47);根据暴露时间的长短(OR> 30天:12.55,95%CI 1.73–90.88)和更高的剂量(OR 10.69,95%CI 4.02–28.44),风险增加。布洛芬,建议剂量(OR 1.92,95%CI 1.13–3.26)和更高剂量(OR 3.73,95%CI 1.11–12.46)以及酮洛芬≥150 mg(OR 4.65, 95%CI 1.33–10.00)。结论:在所有非甾体抗炎药中,尼美舒利与较高的风险相关,布洛芬和高剂量的酮洛芬也与肝毒性的风险适度增加相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号